Top

Published in:

01-10-2010

Genetics of Menstrual Migraine: The Molecular Evidence

Authors: Natalie Colson, Francesca Fernandez, Lyn Griffiths

Published in: Current Pain and Headache Reports | Issue 5/2010

Abstract

Migraine is considered to be a multifactorial disorder in which genetic, environmental, and, in the case of menstrual and menstrually related migraine, hormonal events influence the phenotype. Certainly, the role of female sex hormones in migraine has been well established, yet the mechanism behind this well-known relationship remains unclear. This review focuses on the potential role of hormonally related genes in migraine, summarizes results of candidate gene studies to date, and discusses challenges and issues involved in interpreting hormone-related gene results. In light of the molecular evidence presented, we discuss future approaches for analysis with the view to elucidate the complex genetic architecture that underlies the disorder.

Couturier EG, Bomhof MA, Neven AK, van Duijn NP: Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003, 23:302–308.CrossRefPubMed

MacGregor EA: "Menstrual" migraine: towards a definition. Cephalalgia 1996, 16:11–21.CrossRefPubMed

Lipton RB, Stewart WF: Prevalence and impact of migraine. Neurol Clin 1997, 15:1–13.CrossRefPubMed

•• Gupta S, Mehrotra S, Villalón CM, et al.: Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther 2007, 113:321–340. This review details the changes in migraine throughout the female reproductive cycle and discusses the vascular and neuronal effects of sex hormones and how they may play a role in migraine.CrossRefPubMed

MacGregor EA, Chia H, Vohrah RC, Wilkinson M: Migraine and menstruation: a pilot study. Cephalalgia 1990, 10:305–310.CrossRefPubMed

MacGregor EA: Oestrogen and attacks of migraine with and without aura. Lancet Neurol 2004, 3: 354–361.CrossRefPubMed

Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24(Suppl 1):1–60.

Dennerstein L, Morse C, Burrows G, et al.: Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol 1988, 2:113–120.CrossRefPubMed

Smitherman TA, Kolivas ED: Resolution of menstrually related migraine following aggressive treatment for breast cancer. Headache 2010, 50:485–488.CrossRefPubMed

10.

Somerville BW: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972, 22:355–365.PubMed

11.

Epstein MT, Hockaday JM, Hockaday TD: Migraine and reporoductive hormones throughout the menstrual cycle. Lancet 1975, 1:543–548.CrossRefPubMed

12.

Ulrich V, Gervil M, Kyvik KO, et al.: Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. Ann Neurol 1999, 45:242–246.CrossRefPubMed

13.

Gervil M, Ulrich V, Kyvik KO, et al.: Migraine without aura: a population-based twin study. Ann Neurol 1999, 46:606–611.CrossRefPubMed

14.

Gervil M, Ulrich V, Kaprio J, et al.: The relative role of genetic and environmental factors in migraine without aura. Neurology 1999, 53:995–999.PubMed

15.

Mulder EJ, Van Baal C, Gaist D, et al.: Genetic and environmental influences on migraine: a twin study across six countries. Twin Res 2003, 6:422–431.CrossRefPubMed

16.

•• Martin VT, Behbehani M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis: part I. Headache 2006, 46:3–23. This comprehensive review details the effects of steroid hormones in brain pathways believed to be involved in migraine.CrossRefPubMed

17.

Stoffel-Wagner B: Neurosteroid biosynthesis in the human brain and its clinical implications. Ann N Y Acad Sci 2003, 1007:64–78.CrossRefPubMed

18.

Compagnone NA, Mellon SH: Neurosteroids: biosynthesis and function of these novel neuromodulators. Front Neuroendocrinol 2000, 21:1–56.CrossRefPubMed

19.

• Martin VT, Behbehani M: Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis: part 2. Headache 2006, 46:365–386. This review discusses the influence of reproductive events on migraine.CrossRefPubMed

20.

• Varlibas A, Erdemoglu AK: Altered trigeminal system excitability in menstrual migraine patients. J Headache Pain 2009, 10:277–282. This study implicates trigeminal excitability in patients with menstrual migraine.CrossRefPubMed

21.

Martin VT, Lee J, Behbehani MM: Sensitization of the trigeminal sensory system during different stages of the rat estrous cycle: implications for menstrual migraine. Headache 2007, 47:552–563.CrossRefPubMed

22.

Lambert GA, Donaldson C, Hoskin KL, et al.: Dilatation induced by 5-HT in the middle meningeal artery of the anaesthetised cat. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:591–601.CrossRefPubMed

23.

Shevel E: Middle meningeal artery dilatation in migraine. Headache 2009, 49:1541–1543.CrossRefPubMed

24.

Pecins-Thompson M, Brown NA, Kohama SG, Bethea CL: Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996, 16:7021–7029.PubMed

25.

Pecins-Thompson M, Brown NA, Bethea CL: Regulation of serotonin re-uptake transporter mRNA expression by ovarian steroids in rhesus macaques. Brain Res Mol Brain Res 1998, 53:120–129.CrossRefPubMed

26.

Smith LJ, Henderson JA, Abell CW, Bethea CL: Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 2004, 29:2035–2045.CrossRefPubMed

27.

Sabban EL, Maharjan S, Nostramo R, et al.: Divergent effects of estradiol on gene expression of catecholamine biosynthetic enzymes. Physiol Behav 2010, 99:163–168.CrossRefPubMed

28.

Pau KY, Hess DL, Kohama S, et al.: Oestrogen upregulates noradrenaline release in the mediobasal hypothalamus and tyrosine hydroxylase gene expression in the brainstem of ovariectomized rhesus macaques. J Neuroendocrinol 2000, 12:899–909.CrossRefPubMed

29.

Karkanias GB, Ansonoff MA, Etgen AM: Estradiol regulation of alpha 1b-adrenoceptor mRNA in female rat hypothalamus-preoptic area. J Neuroendocrinol 1996, 8:449–455.CrossRefPubMed

30.

Karkanias GB, Petitti N, Etgen AM: Progesterone attenuation of alpha 1-adrenergic receptor stimulation of phosphoinositol hydrolysis in hypothalamus of estrogen-primed female rats. Endocrinology 1995, 136:1993–1999.CrossRefPubMed

31.

Shughrue PJ, Merchenthaler I: Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebral cortex. Front Neuroendocrinol 2000, 21:95–101.CrossRefPubMed

32.

Epperson CN, Haga K, Mason GF, et al.: Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2002, 59:851–858.CrossRefPubMed

33.

• Eikermann-Haerter K, Dileköz E, Kudo C, et al.: Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. J Clin Invest 2009, 119:99–109. This animal study provides evidence for an additive effect of gene mutations and steroid hormones in migraine.PubMed

34.

Eikermann-Haerter K, Baum MJ, Ferrari MD, et al.: Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. Ann Neurol 2009, 66:564–568.CrossRefPubMed

35.

Herynk MH, Fuqua SA: Estrogen receptor mutations in human disease. Endocr Rev 2004, 25:869–898.CrossRefPubMed

36.

Agoulnik IU, Tong XW, Fischer DC, et al.: A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab 2004, 89:6340–6347.CrossRefPubMed

37.

Cenni B, Picard D: Ligand-independent activation of steroid receptors: new roles for old players. Trends Endocrinol Metab 1999, 10:41–46.CrossRefPubMed

38.

Curran JE, Lea RA, Rutherford S, et al.: Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 2001, 95:271–275.CrossRefPubMed

39.

Colson NJ, Lea RA, Quinlan S, et al.: The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. Neurogenetics 2004, 5:129–133.CrossRefPubMed

40.

Colson NJ, Lea RA, Quinlan S, et al.: Investigation of hormone receptor genes in migraine. Neurogenetics 2005, 6:17–23.CrossRefPubMed

41.

Krithivas K, Yurgalevitch SM, Mohr BA, et al.: Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J Endocrinol 1999, 162:137–142.CrossRefPubMed

42.

Donaldson CJ, Crapanzano JP, Watson JC, et al.: PROGINS Alu insertion and human genomic diversity. Mutat Res 2002, 501:137–141.PubMed

43.

Schuit SC, de Jong FH, Stolk L, et al.: Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol 2005, 153:327–334.CrossRefPubMed

44.

Shearman AM, Cooper JA, Kotwinski PJ, et al.: Estrogen receptor alpha gene variation and the risk of stroke. Stroke 2005, 36:2281–2282.CrossRefPubMed

45.

Colson NJ, Lea RA, Quinlan S, Griffiths LR: No role for estrogen receptor 1 gene intron 1 Pvu II and exon 4 C325G polymorphisms in migraine susceptibility. BMC Med Genet 2006, 7:12.CrossRefPubMed

46.

Oterino A, Pascual J, Ruiz de Alegría C, et al.: Association of migraine and ESR1 G325C polymorphism. Neuroreport 2006, 17:61–64.CrossRefPubMed

47.

Kaunisto MA, Kallela M, Hämäläinen E, et al.: Testing of variants of the MTHFR and ESR1 genes in 1798 Finnish individuals fails to confirm the association with migraine with aura. Cephalalgia 2006, 26:1462–1472.CrossRefPubMed

48.

Lee H, Sininger L, Jen JC, et al.: Association of progesterone receptor with migraine-associated vertigo. Neurogenetics 2007, 8:195–200.CrossRefPubMed

49.

• Oterino A, Toriello M, Cayón A, et al.: Multilocus analyses reveal involvement of the ESR1, ESR2, and FSHR genes in migraine. Headache 2008, 48:1438–1450. This study provides evidence for genetic interaction between three hormonally related genes.

50.

Corominas R, Ribasés M, Cuenca-León E, et al.: Lack of association of hormone receptor polymorphisms with migraine. Eur J Neurol 2009, 16:413–415.CrossRefPubMed

51.

Joshi G, Pradhan S, Mittal B: Role of the oestrogen receptor (ESR1 PvuII and ESR1 325 C-- > G) and progesterone receptor (PROGINS) polymorphisms in genetic susceptibility to migraine in a North Indian population. Cephalalgia 2010, 30:311–320.PubMed

52.

Yang Q, Khoury MJ, Friedman J, et al.: How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005, 34:1129–1137.CrossRefPubMed

53.

Gorroochurn P, Hodge SE, Heiman GA, et al.: Non-replication of association studies: "pseudo-failures" to replicate? Genet Med 2007, 9:325–331.CrossRefPubMed

54.

Welch KM, Brandes JL, Berman NE: Mismatch in how oestrogen modulates molecular and neuronal function may explain menstrual migraine. Neurol Sci 2006, 27(Suppl 2):S190–S192.CrossRefPubMed

55.

Puri V, Cui L, Liverman CS, et al.: Ovarian steroids regulate neuropeptides in the trigeminal ganglion. Neuropeptides 2005, 39:409–417.CrossRefPubMed

Title: Genetics of Menstrual Migraine: The Molecular Evidence
Authors: Natalie Colson
Francesca Fernandez
Lyn Griffiths
Publication date: 01-10-2010
Publisher: Current Science Inc.
Published in: Current Pain and Headache Reports / Issue 5/2010
Print ISSN: 1531-3433
Electronic ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-010-0129-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genetics of Menstrual Migraine: The Molecular Evidence

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Coping Strategies in Chronic Pain

New Trends in the Treatment and Management of Myofascial Pain Syndrome

Effect of Treatment on Trigger Points

Sex Hormones and Pain: The Evidence From Functional Imaging

Clinical Trials Report: Sumatriptan–Naproxen Combination for Symptomatic Treatment of Comorbid Dysmenorrhea and Migraine

Health-related Quality of Life in Patients with Myofascial Pain Syndrome